NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 7 December 2021 09:15am

**Location:** Zoom Webinar

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Mr Alan Thomas Present for all items
5. Ms Ana Duarte Present for all items
6. Mr Andrew Champion Present for items 1 to 4.2.2
7. Dr Craig Buckley Present for all items
8. Dr David Maudgil Present for items 1 to 4.2.2
9. Mr Dominic Pivonka Present for items 1 to 4.2.2
10. Dr Fiona MacPherson-Smith Present for items 1 to 4.2.2
11. Professor G.J Melendez-Torres Present for all items
12. Mr Hugo Pedder Present for all items
13. Dr Justin Daniels Present for all items
14. Professor Khalida Ismail Present for all items
15. Dr Michael Holmes Present for all items
16. Dr Mohit Sharma Present for all items
17. Mr Richard Ballerand Present for all items
18. Dr Rita Faria Present for all items
19. Dr Roger Whittaker Present for all items
20. Dr Steve Edwards Present for all items
21. Dr Charles Crawley Present for all items

NICE staff present

James Devine, Coordinator Present for all items

Shonagh D’Sylva, Project manager Present for items 1 to 4.22

Thomas Feist, Project manager Present for all items

Catherine Pank, Assistant project Present for all items

manager

Henry Edwards, Associate director Present for items 1 to 4.2.2

Ewa Rupniewska, Technical Present for items 1 to 4.2.2

adviser

Sarah Wilkes, Technical analyst Present for items 1 to 4.2.2

Janet Robertson, Associate director Present for item 5

Mary Hughes, Technical adviser Present for item 5

Sana Khan, Technical analyst Present for item 5

Laura Marsden, PIP adviser Present for all items

Steph Armstrong, Health economics Present for all items

analyst

Samuel Slayen, TA analyst Present for all items

Ella Livingstone, Technical Present for all items

adviser – commercial liaison (PASLU)

Thomas Strong, HTA advisor (Cancer Present for all items

Drugs Fund)

Emily Eaton-Turner, Technical analyst Present for all items

- commercial liaison (PASLU)

Korin Knight, Senior medical editor Present for items 1 to 4.2.2

Hayley Garnett, Senior medical editor Present for item 5

Charlotte Campion, Project manager Present for all items

Alexandra Sampson, Technical analyst Present for all items

Federica Ciamponi, Scientific adviser Present for all items

Laura Kelly, COT administrator Present for all items

Evidence Review Group representatives present

Joanne Lord, SHTAC Present for items 1 to 4.1.3

David Scott, SHTAC Present for items 1 to 4.1.3

Paul Tappenden, ScHARR Present for items 5.1 to 5.1.3

Andrew Merty, ScHARR Present for items 5.1 to 5.1.3

Clinical & patient experts present

Professor Peter Clark, NHS England Present for all items

CDF Lead

Alicia Okines, Clinical expert Present for items 1 to 4.1.3

Dr Dima El-Sharkawi, Clinical expert Present for items 5.1 to 5.1.3

Dr Shirley D’Sa, Clinical expert Present for items 5.1 to 5.1.3

Mr David Smith, Patient expert Present for items 5.1 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Sarah Parry, Sumithra Maheswaran, and Peter Baker-Gulliver.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 2 November 2021

### Evaluation of Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Seattle Genetics
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Okines has received a speaker fee and was compensated for work on an advisory board panel for Seagen, she has also participated in an advisory board for Roche and AstraZeneca and Daiichi Sankyo. Her institution received research funding from Pfizer and Roche and she received travel support to attend ESMO 2019 from Leo Pharmaceuticals. She received speaker’s fees from Pfizer, Lilly and AstraZeneca and registration for ASCO 2021 and ESMO 2021 was received from Lilly. It was agreed that these declarations would not prevent her from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

Further updates will be available on the topic webpage in due course: https://www.nice.org.uk/guidance/indevelopment/gid-ta10708/documents.

### Appraisal of Ibrutinib for treating Waldenstrom’s macroglobulinaemia (CDF Review of TA491) [ID3778]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen-Cilag
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Dima El-Sharkawi declared a direct financial interest as she has received honoraria for educational talks on ibrutinib. She also declared an indirect financial interest as WMUK have received money from Janssen for the running of a national registry. It was agreed that these declarations would not prevent her from providing expert advice to the committee.
* Dr Shirley D’Sa declared a direct financial interest as she is on the Medical Advisory Board of BeigGene UK Ltd and has received honoraria for this and speaker’s fees. She also declared an indirect financial interest as her research fund has received grants from Janssen, she has worked on projects with Janssen to collect and analyse data from the RMR. It was agreed that these declarations would not prevent her from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Steve Edwards (costing lead), and Michael Holmes (clinical lead).
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Further updates will be available on the topic webpage in due course: https://www.nice.org.uk/guidance/indevelopment/gid-ta10827/documents

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 18 January 2022 and will start promptly at 09:30am.